Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Has announcements × Urothelial Cancer × erdafitinib × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Active not recruiting 2

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Urothelial Cancer 2

Interventions

pembrolizumab 2 erdafitinib 2 Gemcitabine 2 Cisplatin 2 Carboplatin 2 vinflunine 1 enfortumab vedotin 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02365597 2026-03-19

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting

239 enrolled 32 charts 1 FDA

Urothelial Cancer

NCT03390504 2026-02-02

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡